Mylan Increases Injectable Presence, But In Declining Market
This article was originally published in PharmAsia News
Executive Summary
The generics company added to its arsenal of injectable drugs by acquiring rights to Aspen’s DVT treatment Arixtra, but the anticoagulant faces tough competition from oral entrants.